(TIVC)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
| Name | Position |
|---|---|
| Ms. Lisa G. Wolf | CFO and Principal Financial & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | 8-K | tivic_8k.htm |
| 2026-03-13 | 8-K | tivic_8k.htm |
| 2026-03-11 | 8-K | tivic_8k.htm |
| 2026-03-04 | 8-K | tivic_8k.htm |
| 2026-01-09 | DEF 14A | tivic_def14a.htm |
| 2025-12-29 | S-3 | tivicpreferred_s3.htm |
| 2025-12-11 | 8-K | tivic_8k.htm |
| 2025-11-18 | 8-K | tivc20251117_8k.htm |
| 2025-11-14 | 10-Q | tivc20250930_10q.htm |
| 2025-11-13 | 8-K | tivic_8k.htm |